SINOVAC BIOTECH LTD's ticker is SVA and the CUSIP is P8696W104. A total of 45 filers reported holding SINOVAC BIOTECH LTD in Q3 2014. The put-call ratio across all filers is 60.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,000 | 0.0% | 656 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | -99.4% | 656 | -96.8% | 0.00% | – |
| Q4 2017 | $163,000 | -6.3% | 20,700 | -16.3% | 0.00% | – |
| Q3 2017 | $174,000 | +4.2% | 24,739 | 0.0% | 0.00% | – |
| Q2 2017 | $167,000 | +17.6% | 24,739 | 0.0% | 0.00% | – |
| Q1 2017 | $142,000 | -3.4% | 24,739 | -0.8% | 0.00% | – |
| Q4 2016 | $147,000 | -72.1% | 24,938 | -72.1% | 0.00% | – |
| Q3 2016 | $527,000 | +47.2% | 89,428 | +48.2% | 0.00% | – |
| Q2 2016 | $358,000 | +40.4% | 60,343 | +24.3% | 0.00% | – |
| Q2 2015 | $255,000 | +26.9% | 48,551 | +20.0% | 0.00% | – |
| Q1 2015 | $201,000 | +93.3% | 40,456 | +103.0% | 0.00% | – |
| Q4 2014 | $104,000 | +103.9% | 19,926 | +85.3% | 0.00% | – |
| Q3 2014 | $51,000 | -40.0% | 10,756 | -27.9% | 0.00% | – |
| Q2 2014 | $85,000 | -75.5% | 14,918 | -69.1% | 0.00% | – |
| Q1 2014 | $347,000 | +122.4% | 48,244 | +85.8% | 0.00% | – |
| Q3 2013 | $156,000 | – | 25,961 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 2,718,735 | $340,000,000 | 7.22% |
| Vivo Capital, LLC | 5,900,000 | $38,173,000 | 4.18% |
| Neumann Advisory Hong Kong Ltd | 315,586 | $2,042 | 0.82% |
| Financial Gravity Asset Management, Inc. | 988 | $3,197,686 | 0.04% |
| Yorktown Management & Research Co Inc | 149,786 | $4,494 | 0.01% |
| Renaissance Technologies | 2,375,841 | $1,537 | 0.00% |
| WELLS FARGO & COMPANY/MN | 1,661 | $10,747 | 0.00% |
| NORTHERN TRUST CORP | 13,787 | $0 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GROUP ONE TRADING, L.P. | 412 | $2,666 | 0.00% |